Hydroxychloroquine

"Hydroxychloroquine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)

Descriptor ID	D006886
MeSH Number(s)	D03.633.100.810.050.180.350
Concept/Terms	Hydroxychloroquine Hydroxychloroquine Oxychlorochin Oxychloroquine Hydroxychlorochin Plaquenil Plaquenil Hydroxychloroquine Sulfate Hydroxychloroquine Sulfate Hydroxychloroquine Sulfate (1:1) Salt

Below are MeSH descriptors whose meaning is more general than "Hydroxychloroquine".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, Fused-Ring [D03.633]
Heterocyclic Compounds, 2-Ring [D03.633.100]
Quinolines [D03.633.100.810]
Aminoquinolines [D03.633.100.810.050]
Chloroquine [D03.633.100.810.050.180]
Hydroxychloroquine [D03.633.100.810.050.180.350]

Below are MeSH descriptors whose meaning is related to "Hydroxychloroquine".

Below are MeSH descriptors whose meaning is more specific than "Hydroxychloroquine".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Hydroxychloroquine" by people in this website by year, and whether "Hydroxychloroquine" was a major or minor topic of these publications.

Bar chart showing 29 publications over 13 distinct years, with a maximum of 9 publications in 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	0	1	1
2003	1	1	2
2004	1	0	1
2005	0	1	1
2007	1	0	1
2011	2	0	2
2013	0	1	1
2014	4	0	4
2016	1	0	1
2018	0	1	1
2020	3	6	9
2021	2	2	4
2023	1	0	1

Below are the most recent publications written about "Hydroxychloroquine" by people in Profiles.

Hidekawa C, Yoshimi R, Saigusa Y, Tamura J, Kojitani N, Suzuki N, Sakurai N, Yoshioka Y, Sugiyama-Kawahara Y, Kunishita Y, Kishimoto D, Higashitani K, Sato Y, Komiya T, Nagai H, Hamada N, Maeda A, Tsuchida N, Hirahara L, Soejima Y, Takase-Minegishi K, Kirino Y, Yajima N, Sada KE, Miyawaki Y, Ichinose K, Ohno S, Kajiyama H, Sato S, Shimojima Y, Fujiwara M, Nakajima H. Protective effect of hydroxychloroquine on infections in patients with systemic lupus erythematosus: an observational study using the LUNA registry. Front Immunol. 2023; 14:1227403.

View in: PubMed
Liu HH, Ezekowitz MD, Columbo M, Khan O, Martin J, Spahr J, Yaron D, Cushinotto L, Kapelusznik L. The future is now: our experience starting a remote clinical trial during the beginning of the COVID-19 pandemic. Trials. 2021 Sep 07; 22(1):603.

View in: PubMed
Coppock D, Baram M, Chang AM, Henwood P, Kubey A, Summer R, Zurlo J, Li M, Hess B. COVID-19 treatment combinations and associations with mortality in a large multi-site healthcare system. PLoS One. 2021; 16(6):e0252591.

View in: PubMed
Ichikawa K, Kirino Y, Kunishita Y, Kishimoto D, Takase-Minegishi K, Yoshimi R, Nakajima H. Initial hydroxychloroquine monotherapy in systemic lupus erythematosus: report of three cases. Mod Rheumatol Case Rep. 2021 07; 5(2):259-264.

View in: PubMed
Chopra D, Boparai JK, Bhandari B, Srivastava A, Gupta R. Pharmacological Strategies for COVID-19 - A Review of the Most Promising Repurposed Antiviral Drugs. Infect Disord Drug Targets. 2021; 21(7):e160921189260.

View in: PubMed
Roomi S, Ullah W, Ahmed F, Farooq S, Sadiq U, Chohan A, Jafar M, Saddique M, Khanal S, Watson R, Boigon M. Efficacy of Hydroxychloroquine and Tocilizumab in Patients With COVID-19: Single-Center Retrospective Chart Review. J Med Internet Res. 2020 09 01; 22(9):e21758.

View in: PubMed
Hiedra R, Lo KB, Elbashabsheh M, Gul F, Wright RM, Albano J, Azmaiparashvili Z, Patarroyo Aponte G. The use of IV vitamin C for patients with COVID-19: a case series. Expert Rev Anti Infect Ther. 2020 Dec; 18(12):1259-1261.

View in: PubMed
Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, Humphrey LL. Update Alert 2: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians. Ann Intern Med. 2020 09 01; 173(5):W88-W89.

View in: PubMed
Nasir N, Farooqi J, Mahmood SF, Jabeen K. COVID-19-associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID-19 pneumonia: An observational study from Pakistan. Mycoses. 2020 Aug; 63(8):766-770.

View in: PubMed
Salacup G, Lo KB, Gul F, Peterson E, De Joy R, Bhargav R, Pelayo J, Albano J, Azmaiparashvili Z, Benzaquen S, Patarroyo-Aponte G, Rangaswami J. Characteristics and clinical outcomes of COVID-19 patients in an underserved-inner city population: A single tertiary center cohort. J Med Virol. 2021 01; 93(1):416-423.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement